Clinical efficacy of cabozantinib in two pediatric patients with recurrent renal cell carcinoma.

about

Clinical efficacy of cabozantinib in two pediatric patients with recurrent renal cell carcinoma.

Item

http://www.wikidata.org/entity/Q38833200

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Clinical efficacy of cabozanti ...... ecurrent renal cell carcinoma.

@en

type

Item

label

Clinical efficacy of cabozanti ...... ecurrent renal cell carcinoma.

@en

prefLabel

Clinical efficacy of cabozanti ...... ecurrent renal cell carcinoma.

@en

P1476

Clinical efficacy of cabozanti ...... ecurrent renal cell carcinoma.

@en

P2093

Mark Ranalli

http://www.w3.org/2001/XMLSchema#string

Mary Frances Wedekind

http://www.w3.org/2001/XMLSchema#string

Nilay Shah

http://www.w3.org/2001/XMLSchema#string

P2860

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition.

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers

Characterization of adolescent and pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN03B2.

Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis.

Translocation renal cell carcinomas in adults: a single-institution experience.

Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature.

A phase I study of cabozantinib (XL184) in patients with renal cell cancer.

Pediatric and adolescent renal cell carcinoma.

P31

scholarly article

P356

10.1002/PBC.26586

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28417541

http://www.w3.org/2001/XMLSchema#string